Comparative Effectiveness of Tezepelumab and Dupilumab in Asthma: A Multinational Retrospective Cohort Study
No significant difference in exacerbation risk was found between dupilumab and tezepelumab. Because residual confounding may exist, further investigation is warranted to guide the selection of biological therapies in clinical practice.
Authors
- Caixia An
- Chun‐Tse Hung (ORCID: https://orcid.org/0000-0002-3485-9775)
- Yu-Chien Hung (ORCID: https://orcid.org/0009-0000-7376-5643)
- Chi-Won Suk
Institutions
- National Yang Ming Chiao Tung University (TW)
- University of Michigan (US)
- Taipei Medical University Hospital (TW)
- Wan Fang Hospital (TW)
- Taipei Medical University (TW)
Publication Details
- Journal
- The Journal of Allergy and Clinical Immunology In Practice
- Published
- 2025-11-28
- DOI
- https://doi.org/10.1016/j.jaip.2025.11.024
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00